Proteoglycans: Key partners in bone cell biology

BioEssays

Volumn 29, Issue 8, 2007, Pages 758-771

  Lamoureux, François ^a   Baud'huin, Marc ^a   Duplomb, Laurence ^a   Heymann, Dominique ^a   Rédini, Françoise ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; AGRIN; BIGLYCAN; BREVICAN; CHONDROITIN SULFATE; COLLAGEN FIBRIL; CYTOKINE; DECORIN; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; GLYPICAN 1; GLYPICAN 3; GROWTH FACTOR; HEPARAN SULFATE; HEPARIN; HYALURONIC ACID; KERATAN SULFATE; KERATOCAN; LUMICAN; MIMECAN; NEUROCAN; OSTEOPROTEGERIN; PERLECAN; PROTEOGLYCAN; SYNDECAN 1; SYNDECAN 2; SYNDECAN 3; SYNDECAN 4; TRANSFORMING GROWTH FACTOR BETA; VERSICAN;

BONE CELL; BONE DEVELOPMENT; BONE DISEASE; BONE MATRIX; BONE TUMOR; CARCINOGENESIS; CHONDRODYSPLASIA; CROUZON SYNDROME; CYTOLOGY; EHLERS DANLOS SYNDROME; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; MORPHOGENESIS; MUSCULAR DYSTROPHY; NONHUMAN; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; BONE NEOPLASMS; BONE RESORPTION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; MODELS, BIOLOGICAL; PROTEOGLYCANS;

EID: 34547631499     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20612     Document Type: Review

References (107)

1. Hardingham TE, Fosang AJ. 1992. Proteoglycans: many forms and many functions. FASEB J 6:861-870.
2. Ruoslahti E. 1988. Structure and biology of proteoglycans. Annu Rev Cell Biol 4:229-255.
3. nd Ed, Oxford University Press.
4. Iozzo RV. 1998. Matrix proteoglycans: From molecular design to cellular function. Annu Rev Biochem 67:609-652.
5. Leaver AG, Triffitt JT, Holbrook IB. 1975. Newer knowledge of non-collagenous protein in dentin and cortical bone matrix. Clin Orthop Relat Res 110:269-292.
6. Waddington RJ, Roberts HC, Sugars RV, Schonherr E. 2003. Differential roles for small leucine-rich proteoglycans in bone formation. Europ Cell Mater 6:12-21.
7. Ingram RT, Clarke BL, Fisher LW, Fitzpatrick LA. 1993. Distribution of noncollagenous proteins in the matrix of adult human bone: evidence of anatomic and functional heterogeneity. J Bone Miner Res 8:1019-1029.
8. Alini M, Roughley PJ. 2001. Changes in leucine-rich repeat proteoglycans during maturation of the bovine growth plate. Matrix Biol 19:805-813.
9. Saamanen AM, Salminen HJ, Rantakokko AJ, Heinegard D, Vuorio EI. 2001. Murine fibromodulin: cDNA and genomic structure, and age-related expression and distribution in the knee joint. Biochem J 355:577-585.
10. Ezura Y, Chakravarti S, Oldberg A, Chervoneva I, Birk DE. 2000. Differential expression of lumican and fibromodulin regulate collagen fibrillogenesis in developing mouse tendons. J Cell Biol 151:779-788.
11. Raouf A, Seth A. 2002. Discovery of osteoblast-associated genes using cDNA microarrays. Bone 30:463-471.
12. Wendel M, Sommarin Y, Heinegard D. 1998. Bone matrix proteins: isolation and characterization of a novel cell-binding keratan sulfate proteoglycan (osteoadherin) from bovine bone. J Cell Biol 141:839-847.
13. Shinomura T, Kimata K. 1992. Proteoglycan-Lb, a small dermatan sulfate proteoglycan expressed in embryonic chick epiphyseal cartilage, is structurally related to osteoinductive factor. J Biol Chem 267:1265-1270.
14. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, et al. 1997. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 136:729-743.
15. Corsi A, Xu T, Chen XD, Boyde A, Liang J, et al. Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J Bone Miner Res 17:1180-1189.
16. Weber IT, Harrison RW, Iozzo RV. 1996. Model structure of decorin and implications for collagen fibrillogenesis. J Biol Chem 271:31767-31770.
17. Xu T, Bianco P, Fisher LW, Longenecker G, Smith E, et al. 1998. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet 20:78-82.
18. Chen XD, Shi S, Xu T, Robey PG, Young MF. 2002. Age-related osteoporosis in biglycan-deficient mice is related to defects in bone marrow stromal cells. J Bone Miner Res 17:331-340.
19. Svensson L, Narlid I, Oldberg A. 2000. Fibromodulin and lumican bind to the same region on collagen type I fibrils. FEBS Lett 470:178-182.
20. Chakravarti S. 2002. Functions of lumican and fibromodulin: lessons from knockout mice. Glycoconj J 19:287-293.
21. Hildebrand A, Romaris M, Rasmussen LM, Heinegard D, Twardzik DR, et al. 1994. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 302:527-534.
22. Takeuchi Y, Kodama Y, Matsumoto T. 1994. Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity. J Biol Chem 269:32634-32638.
23. Hausser H, Groning A, Hasilik A, Schonherr E, Kresse H. 1994. Selective inactivity of TGF-beta/decorin complexes. FEBS Lett 353:243-245.
24. Markmann A, Hausser H, Schonherr E, Kresse H. 2000. Influence of decorin expression on transforming growth factor-beta-mediated collagen gel retraction and biglycan induction. Matrix Biol 19:631-636.
25. Bi Y, Stuelten CH, Kilts T, Wadhwa S, Iozzo RV, et al. 2005. Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. J Biol Chem 280:30481-30489.
26. Hayashi Y, Liu CY, Jester JJ, Hayashi M, Wang IJ, et al. 2005. Excess biglycan causes eyelid malformation by perturbing muscle development and TGF-alpha signalling. Dev Biol 277:222-234.
27. Tufvesson E, Westergren-Thorsson G. 2002. Tumour necrosis factor-alpha interacts with biglycan and decorin. FEBS Lett 530:124-128.
28. Kinsella MG, Bressler SL, Wight TN. 2004. The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. Crit Rev Eukaryot Gene Exp 14:203-234.
29. Chen XD, Fisher LW, Robey PG, Young MF. 2004. The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation. FASEB J 18:948-958.
30. Mochida Y, Parisuthiman D, Yamauchi M. 2006. Biglycan is a positive modulator of BMP-2 induced osteoblast differentiation. Advances in Exp Med Biol 585:101-113.
31. Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B, et al. 1997. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 100:149-157.
32. Waddington RJ, Hall RC, Embery G, Lloyd DM. 2003. Changing profiles of proteoglycans in the transition of predentine to dentine. Matrix Biol 22:153-161.
33. Wong M, Lawton T, Goetinck PF, Kuhn JL, Goldstein SA, et al. 1992. Aggrecan core protein is expressed in membranous bone of the chick embryo. Molecular and biomechanical studies of normal and nanomelia embryos. J Biol Chem 267:5592-5598.
34. Liu Y, Watanabe H, Nifuji A, Yamada Y, Olson EN, et al. 1997. Overexpression of a single helix-loop-helix-type transcription factor, scleraxis, enhances aggrecan gene expression in osteoblastic osteosarcoma ROS17/2.8 cells. J Biol Chem 272:29880-29885.
35. Noonan KJ, Stevens JW, Tammi R, Tammi M, Hernandez JA, et al. 1996. Spatial distribution of CD44 and hyaluronan in the proximal tibia of the growing rat. J Orthop Res 14:573-581.
36. Robey PG. 1996. Vertebrate mineralized matrix proteins: structure and function. Connect Tissue Res 35:131-136.
37. Nakamura H, Ozawa H. 1994. Immunohistochemical localization of heparan sulfate proteoglycan in rat tibiae. J Bone Miner Res 9:1289-1299.
38. McQuillan DJ, Midura RJ, Hascall VC, Yanagishita M. 1992. Plasmamembrane-intercalated heparan sulphate proteoglycans in an osteogenic cell line (UMR106-01 BSP). Biochem J 285:25-33.
39. Pacifici M, Shimo T, Gentili C, Kirsch T, Freeman TA, et al. 2005. Syndecan-3: a cell-surface heparan sulfate proteoglycan important for chondrocyte proliferation and function during limb skeletogenesis. J Bone Miner Metab 23:191-199.
40. Koyama E, Shimazu A, Leatherman JL, Golden EB, Nah HD, et al. 1996. Expression of syndecan-3 and tenascin-C: possible involvement in periosteum development. J Orthop Res 14:403-412.
41. Ruoslahti E, Yamaguchi Y. 1991. Proteoglycans as modulators of growth factor activities. Cell 64:867-869.
42. Gallagher JT, Turnbull JE, Lyon M. 1992. Patterns of sulphation in heparan sulphate: polymorphism based on a common structural theme. Int J Biochem 24:553-560.
43. Casu B, Petitou M, Provasoli M, Sinai P. 1988. Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem Sci 13:221-225.
44. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, et al. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729-777.
45. Park PW, Reizes O, Bernfield M. 2000. Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. J Biol Chem 275:29923-29926.
46. Govindraj P, West L, Koob TJ, Neame P, Doege K, et al. 2002. Isolation and identification of the major heparan sulfate proteoglycans in the developing bovine rib growth plate. J Biol Chem 277:19461-19469.
47. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y. 1999. Perlecan is essential for cartilage and cephalic development. Nat Genet 23:354-358.
48. Costell M, Gustafsson E, Aszodi A, Morgelin M, Bloch W, et al. 1999. Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol 147:1109-1122.
49. Smith SM, West LA, Govingraj P, Zhang X, Ornitz DM, et al. 2007. Heparan and chondroitin sulfate on growth plate perlecan mediate binding and delivery of FGF-2 to FGF receptors. Matrix Biol 26:175-184.
50. Kinne RW, Fisher LW. 1987. Keratan sulfate proteoglycan in rabbit compact bone is bone sialoprotein II. J Biol Chem 262:10206-10211.
51. Wadhwa S, Embree MC, Bi Y, Young MF. 2004. Regulation, regulatory activities, and function of biglycan. Crit Rev Eukaryot Gene Expr 14:301-315.
52. Bianco P, Fisher LW, Young MF, Termine JD, Robey PG. 1990. Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. J Histochem Cytochem 38:1549-1563.
53. Gori F, Schipani E, Demay MB. 2001. Fibromodulin is expressed by both chondrocytes and osteoblasts during fetal bone development. J Cell Biochem 82:46-57.
54. Farach-Carson MC, Hecht JT, Carson DD. 2005. Heparan sulfate proteoglycans: key players in cartilage biology. Crit Rev Eukaryot Gene Expr 15:29-48.
55. David G, Bai XM, Van der Schueren B, Marynen P, Cassiman JJ, et al. 1993. Spatial and temporal changes in the expression of fibroglycan (syndecan-2) during mouse embryonic development. Development 119:841-854.
56. Molteni A, Modrowski D, Hott M, Marie PJ. 1999. Differential expression of fibroblast growth factor receptor-1, -2, and -3 and syndecan-1, -2, and -4 in neonatal rat mandibular condyle and calvaria during osteogenic differentiation in vitro. Bone 24:337-347.
57. Kosher RA. 1998. Syndecan-3 in limb skeletal development. Microsc Res Tech 43:123-130.
58. Handler M, Yurchenco PD, Iozzo RV. 1997. Developmental expression of perlecan during murine embryogenesis. Dev Dyn 210:130-145.
59. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, et al. 2004. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15:457-475.
60. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
61. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
62. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, et al. 2002. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100:3002-3007.
63. Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn DH, et al. 2005. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab 90:2964-2971.
64. Theoleyre S, Kwan Tat S, Vusio P, Blanchard F, et al. 2006. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun 347:460-467.
65. Nakano K, Okada Y, Saito K, Tanaka Y. 2004. Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis Rheum 50:2450-2458.
66. Li Z, Yasuda Y, Li W, Bogyo M, Katz N, et al. 2004. Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J Biol Chem 279:5470-5479.
67. Nikitovic D, Zafiropoulos A, Tzanakakis GN, Karamanos NK, Tsatsakis AM. 2005. Effects of glycosaminoglycans on cell proliferation of normal osteoblasts and human osteosarcoma cells depend on their type and fine chemical compositions. Anticancer Res 25:2851-2856.
68. Muir JM, Andrew M, Hirsh J, Weitz JI, Young E, et al. 1996. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 88:1314-1320.
69. Chowdhury MH, Hamada C, Dempster DW. 1992. Effects of heparin on osteoclast activity. J Bone Miner Res 7:771-777.
70. Walton KJ, Duncan JM, Deschamps P, Shaughnessy SG. 2002. Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood 100:2530-2536.
71. Folwarczna J, Sliwinski L, Janiec W, Pikul M. 2005. Effects of standard heparin and low-molecular-weight heparins on the formation of murine osteoclasts in vitro. Pharmacol Rep 57:635-645.
72. Kram V, Zcharia E, Yacoby-Zeevi O, Metzger S, Chajek-Shaul T, et al. 2006. Heparanase is expressed in osteoblastic cells and stimulates bone formation and bone mass. J Cell Physiol 207:784-792.
73. Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, et al. 1996. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 12:241-247.
74. Bi Y, Nielsen KL, Kilts TM, Yoon A, A Karsdal M, et al. 2006. Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts. Bone 38:778-786.
75. Sipola A, Nelo K, Hautala T, Ilvesaro J, Tuukkanen J. 2006. Endostatin inhibits VEGF-A induced osteoclastic bone resorption in vitro. BMC Musculoskelet Disord 7:56.
76. de Vries TJ, Schoenmaker T, Beertsen W, van der Neut R, Everts V. 2005. Effect of CD44 deficiency on in vitro and in vivo osteoclast formation. J Cell Biochem 94:954-966.
77. Sanderson RD. 2001. Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 12:89-98.
78. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, et al. 2001. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 98:3352-3357.
79. Beauvais DM, Burbach BJ, Rapraeger AC. 2004. The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol 167:171-181.
80. Gonzalez EM, Mongiat M, Slater SJ, Baffa R, Iozzo RV. 2003. A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth. J Biol Chem 278:38113-38116.
81. Woods A, Couchman JR. 1998. Syndecans: synergistic activators of cell adhesion. Trends in Cell Biol 8:189-192.
82. Chilosi M, Adami F, Lestani M, Montagna L, Cimarosto L, et al. 1999. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol 12:1101-1106.
83. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, et al. 2000. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95:388-392.
84. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS. 2001. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 14:1052-1058.
85. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, et al. 2002. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100:610-617.
86. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, et al. 2003. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98:474-483.
87. Mennerich D, Vogel A, Klaman I, Dahl E, Lichtner RB, et al. 2004. Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur J Cancer 40:1373-1382.
88. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, et al. 2002. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116:278-290.
89. Mundy GR. 2002. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593.
90. Birch MA, Skerry TM. 1999. Differential regulation of syndecan expression by osteosarcoma cell lines in response to cytokines but not osteotropic hormones. Bone 24:571-578.
91. Modrowski D, Basle M, Lomri A, Marie PJ. 2000. Syndecan-2 is involved in the mitogenic activity and signaling of granulocyte-macrophage colony-stimulating factor in osteoblasts. J Biol Chem 275:9178-9185.
92. Modrowski D, Orosco A, Thevenard J, Fromigue O, Marie PJ. 2005. Syndecan-2 overexpression induces osteosarcoma cell apoptosis: Implication of syndecan-2 cytoplasmic domain and JNK signaling. Bone 37:180-189.
93. Vlodavsky I, Goldshmidt O, Zcharia E, Atzmon R, Rangini-Guatta Z, et al. 2002 Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol 12:121-129.
94. Iozzo RV, San Antonio JD. 2001. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 108:349-355.
95. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, et al. 2001. Heparanase as mediator of angiogenesis: mode of action. FASEB J 15:1661-1663.
96. Kato M, Wang H, Kainulainen V, Fitzgerald ML, Ledbetter S, et al. 1998. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 4:691-697.
97. Kelly T, Suva LJ, Huang Y, Macleod V, Miao HQ, et al. 2005. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res 65:5778-5784.
98. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, et al. 2002. Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 21:4765-4777.
99. Schonherr E, Levkau B, Schaefer L, Kresse H, Walsh K. 2001. Decorin-mediated signal transduction in endothelial cells. Involvement of Akt/protein kinase B in up-regulation of p21(WAF1/CIP1) but not p27(KIP1). J Biol Chem 276:40687-40692.
100. Hakkinen L, Strassburger S, Kahari VM, Scott PG, Eichstetter I, et al. 2000. A role for decorin in the structural organization of periodontal ligament. Lab Invest 80:1869-1880.
101. Teicher BA, Maehara Y, Kakeji Y, Ara G, Keyes SR, et al. 1997. Reversal of in vivo drug resistance by the transforming growth factor-beta inhibitor decorin. Int J Cancer 71:49-58.
102. Liu D, Shriver Z, Venkataraman G, El Shabrawi Y, Sasisekharan R. 2002. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci USA 99:568-573.
103. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, et al. 2003. QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol 162:341-351.
104. Lai JP, Chien J, Strome SE, Staub J, Montoya DP, et al. 2004. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 23:1439-1447.
105. Cardin AD, Weintraub HJ. 1989. Molecular modeling of protein- glycosaminoglycan interactions. Arteriosclerosis 9:21-32.
106. Belting M, Borsig L, Fuster MM, Brown JR, Persson L, et al. 2002. Tumor attenuation by combined heparan sulfate and polyamine depletion. Proc Natl Acad Sci USA 99:371-376.
107. Smorenburg SM, Van Noorden CJ. 2001. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53:93-105.